Join the Huntington's Disease group to help and get support from people like you.
Huntington's Disease News
Related terms: Huntington Chorea
β-Blocker Use Delays Motor Onset With Huntington Disease
TUESDAY, Dec. 17, 2024 – β-blocker use is associated with delayed motor onset and worsening of motor symptoms with Huntington disease (HD), according to a study published online Dec. 2 in JAMA N...
New Approach to Fight Huntington's Disease Shows Early Promise
MONDAY, Nov. 4, 2024 – Huntington's disease is a devastating, fatal neurological illness with little means of treatment, but a new study in mice offers a glimmer of hope. Huntington's occurs when...
Racial Disparities Identified for Time to Diagnosis of Huntington Disease
FRIDAY, July 26, 2024 – Black individuals are diagnosed with Huntington disease (HD) at least one year later than White individuals, according to a study published online June 21 in Neurology:...
Black Patients Diagnosed With Huntington's Later Than Whites
FRIDAY, July 12, 2024 – Black patients with Huntington’s disease receive their diagnoses an average of one year later than white people with the incurable genetic disorder, a new study shows. Early d...
Teva Announces Austedo XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE) May 29, 2024 -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. ...
Neurocrine Biosciences Announces U.S. FDA Approval of Ingrezza Sprinkle (valbenazine) Capsules
SAN DIEGO, April 30, 2024 /PRNewswire/ – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved Ingrezza Sprinkle (valbenazine) capsules, a...
Neurocrine Biosciences Announces FDA Approval of Ingrezza (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's Disease
SAN DIEGO, Aug. 18, 2023 /PRNewswire/ – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has approved Ingrezza® (valbenazine) capsules for the ...
Teva Announces FDA Approval of Austedo XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of Austedo
New once-daily Austedo XR regimen now approved in 6, 12, and 24 mg tablet strengths Austedo is the only vesicular monoamine transporter 2 (VMAT2) inhibitor approved for both tardive dyskinesia (TD)...
Teva Announces FDA Approval of Austedo (deutetrabenazine) for the Treatment of Chorea Associated with Huntington’s Disease
JERUSALEM--(BUSINESS WIRE)--Apr. 3, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved Austedo...